Patents Assigned to RAYZEBIO, INC.
  • Patent number: 11819556
    Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
    Type: Grant
    Filed: May 26, 2023
    Date of Patent: November 21, 2023
    Assignee: RAYZEBIO, INC.
    Inventors: Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio
  • Patent number: 11707540
    Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: July 25, 2023
    Assignee: RAYZEBIO, INC.
    Inventors: Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio
  • Patent number: 11541134
    Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: January 3, 2023
    Assignee: RAYZEBIO, INC.
    Inventors: Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio
  • Patent number: 11497822
    Abstract: Provided herein are radiopharmaceutical compositions and uses thereof. The radiopharmaceutical compositions can comprise one or more stabilizing agents, an aqueous vehicle, and a conjugate that comprises a targeting ligand and a radionuclide bound to a metal chelator. The targeting ligand can be a small molecule compound or a peptide such as a monocyclic peptide. The targeting ligand can be configured to bind with a tumor target. The stabilizing agent can comprise a radiolysis stabilizer, a free metal chelator, and/or a pH stabilizer. Further provided herein are methods of preparing the radiopharmaceutical compositions and methods of treating cancer by administering the described radiopharmaceutical compositions.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: November 15, 2022
    Assignee: RAYZEBIO, INC.
    Inventors: Daniel Kim, Gang Chen, Ken Song, Matthew Moran, Susan Arangio